We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Plasma Levels Investigated as Alzheimer's Disease Biomarkers

By LabMedica International staff writers
Posted on 04 May 2016
Print article
Image: A diagram of the formation of amyloid plaques in the brain of an Alzheimer brain compared with a normal brain (Photo courtesy of Junji Takano).
Image: A diagram of the formation of amyloid plaques in the brain of an Alzheimer brain compared with a normal brain (Photo courtesy of Junji Takano).
The relationship between plasma levels of two amyloid beta peptides (Aβ1-40 and Aβ1-42), brain volumetrics and cognitive performance has been investigated.

Since amyloid beta (Aβ) peptides are the main component of the amyloid plaques found in Alzheimer patients' brains, changes in levels of Aβ in blood plasma may provide a biomarker for detecting increased risk or early diagnosis of disease.

Scientists at the University of New South Wales (Sydney, Australia) examined 126 age-matched cognitively normal controls, 89 individuals with amnestic mild cognitive impairment (aMCI,) from the Center for Healthy Brain Aging (CHeBA) Sydney Memory & Aging Study (Sydney MAS), as well as 39 individuals with Alzheimer's disease (AD) recruited from a specialty clinic.

Sydney MAS participants underwent brain Magnetic resonance imaging (MRI) scans and were assessed on 19 cognitive measures and were apolipoprotein E (APOE ε4) genotyped. Plasma levels of Aβ1-40 and 1-42 were quantified using enzyme-linked immunosorbent assay (ELISA). Plasma levels of the two peptides and the Aβ1-42/1-40 ratio were lower in aMCI and Alzheimer's disease than in cognitively normal controls, and lower levels of Aβ1-42 were associated with lower global cognition and hippocampal volume and higher levels of white matter hyperintensities, which are believed to contribute to Alzheimer's disease.

A genetic component was also identified, with associations between Aβ1-40 and cognitive and brain volume measures predominantly observed in individuals carrying the ε4 allele, while the opposite was observed in non-carriers. Longitudinal analysis revealed greater decline in global cognition and memory for the highest quintiles of Aβ1-42 and the ratio measure. The relationships of Aβ1-40 and Aβ1-42 were predominantly observed in ε4 allele carriers and non-carriers respectively.

The authors concluded that Plasma Aβ levels and the Aβ1−42/1-40 ratio are related to cognition and hippocampal volumes, with differential associations of Aβ1-40 and Aβ1-42 in ε4 carriers and non-carriers. These data support the Aβ sink model of AD pathology, and suggest that plasma Aβ measures may serve as biomarkers of AD. Anne Poljak, PhD, the lead author of the study, said, “While Aβ has traditionally been measured using cerebrospinal fluid, plasma presents a more accessible sample for routine collection and screening although results to date have been variable.” The study was published on April 18, 2016, in the journal Current Alzheimer Research.

Related Links:
University of New South Wales

Gold Member
Troponin T QC
Troponin T Quality Control
Automated Blood Typing System
IH-500 NEXT
New
CVD Risk Test
GammaCoeur CVD Risk ELISA Test
New
Incubator
HettCube 120

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Molecular Diagnostics

view channel
Image: Heart attacks could be ruled out early with a new test, according to researchers (Photo courtesy of Mindray)

New High-Sensitivity Cardiac Troponin Test Quickly Rules Out Heart Attack

Patients arriving at an emergency department with symptoms like chest or arm pain, indicative of a potential heart attack, often prefer the comfort of home over a hospital bed—especially if they can be... Read more

Hematology

view channel
Image: QScout CBC will give a complete blood count in 2 minutes from fingerstick or venous blood (Photo courtesy of Ad Astra Diagnostics)

Next Gen CBC and Sepsis Diagnostic System Targets Faster, Earlier, Easier Results

Every hour is critical in protecting patients from infections, yet there are currently limited tools to assist in early diagnosis before patients reach a hospital. The complete blood count (CBC) is a common... Read more

Microbiology

view channel
Image: The InfectoSynovia test has the potential to revolutionize the diagnosis of periprosthetic joint infection (Photo courtesy of 123RF)

High-Accuracy Bedside Test to Diagnose Periprosthetic Joint Infection in Five Minutes

Periprosthetic joint infection (PJI) represents a significant global issue that is worsening as the number of joint replacements increases due to aging populations. In the United States alone, the anticipated... Read more

Pathology

view channel
Image: LMU’s Professor Frederick Klauschen developed the novel approach that can improve diagnostic accuracy (Photo courtesy of LMU Munich)

AI Tool Uses Imaging Data to Detect Less Frequent GI Diseases

Artificial intelligence (AI) is already being utilized in various medical fields, demonstrating significant potential in aiding doctors in diagnosing diseases through imaging data. However, training AI... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.